These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24954328)

  • 1. Clinical factors associated with acquisition of resistance to levofloxacin in Stenotrophomonas maltophilia.
    Baek JH; Kim CO; Jeong SJ; Ku NS; Han SH; Choi JY; Yong D; Song YG; Lee K; Kim JM
    Yonsei Med J; 2014 Jul; 55(4):987-93. PubMed ID: 24954328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levofloxacin-resistant Stenotrophomonas maltophilia: risk factors and antibiotic susceptibility patterns in hospitalized patients.
    Wang CH; Yu CM; Hsu ST; Wu RX
    J Hosp Infect; 2020 Jan; 104(1):46-52. PubMed ID: 31505224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital.
    Pien CJ; Kuo HY; Chang SW; Chen PR; Yeh HW; Liu CC; Liou ML
    J Microbiol Immunol Infect; 2015 Jun; 48(3):291-5. PubMed ID: 24239064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia.
    Chong SY; Lee K; Chung HS; Hong SG; Suh Y; Chong Y
    Microb Drug Resist; 2017 Mar; 23(2):163-168. PubMed ID: 27294684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
    Biagi M; Tan X; Wu T; Jurkovic M; Vialichka A; Meyer K; Mendes RE; Wenzler E
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31748318
    [No Abstract]   [Full Text] [Related]  

  • 6. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
    Wei C; Ni W; Cai X; Cui J
    Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of concurrent levofloxacin- and trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia: Risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan.
    Wu RX; Yu CM; Hsu ST; Wang CH
    J Microbiol Immunol Infect; 2022 Feb; 55(1):107-113. PubMed ID: 33500210
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Li LH; Lu HF; Liu YF; Lin YT; Yang TC
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0204321. PubMed ID: 35285252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotics resistance of Stenotrophomonas maltophilia strains isolated from various clinical specimens.
    Çıkman A; Parlak M; Bayram Y; Güdücüoğlu H; Berktaş M
    Afr Health Sci; 2016 Mar; 16(1):149-52. PubMed ID: 27358626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of Delafloxacin and Levofloxacin against Stenotrophomonas maltophilia at Simulated Plasma and Intrapulmonary pH Values.
    Vialichka A; Biagi M; Meyer K; Wu T; Shajee A; Tan X; Wenzler E
    Microbiol Spectr; 2022 Aug; 10(4):e0270521. PubMed ID: 35862943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections.
    Nys C; Cherabuddi K; Venugopalan V; Klinker KP
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427300
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia.
    Palioura S; Gibbons A; Miller D; OʼBrien TP; Alfonso EC; Spierer O
    Cornea; 2018 Mar; 37(3):326-330. PubMed ID: 29408828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections.
    Watson L; Esterly J; Jensen AO; Postelnick M; Aguirre A; McLaughlin M
    J Glob Antimicrob Resist; 2018 Mar; 12():104-106. PubMed ID: 28964955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms.
    Jia W; Wang J; Xu H; Li G
    Int J Environ Res Public Health; 2015 May; 12(5):5177-95. PubMed ID: 25985315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital.
    Duan Z; Qin J; Liu Y; Li C; Ying C
    BMC Microbiol; 2020 Sep; 20(1):294. PubMed ID: 32993493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
    Grillon A; Schramm F; Kleinberg M; Jehl F
    PLoS One; 2016; 11(6):e0156690. PubMed ID: 27257956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of Stenotrophomonas maltophilia meningitis in adults: a high incidence in patients with a postneurosurgical state, long hospital staying and antibiotic use.
    Huang CR; Chen SF; Tsai NW; Chang CC; Lu CH; Chuang YC; Chien CC; Chang WN
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1709-15. PubMed ID: 23611735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis.
    Ko JH; Kang CI; Cornejo-Juárez P; Yeh KM; Wang CH; Cho SY; Gözel MG; Kim SH; Hsueh PR; Sekiya N; Matsumura Y; Lee DG; Cho SY; Shiratori S; Kim YJ; Chung DR; Peck KR
    Clin Microbiol Infect; 2019 May; 25(5):546-554. PubMed ID: 30448331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biofilm Eradication of Stenotrophomonas maltophilia by Levofloxacin and Trimethoprim-Sulfamethoxazole.
    Río-Chacón JMD; Rojas-Larios F; Bocanegra-Ibarias P; Salas-Treviño D; Espinoza-Gómez F; Camacho-Ortiz A; Flores-Treviño S
    Jpn J Infect Dis; 2024 Jul; 77(4):213-219. PubMed ID: 38296539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?
    Cho SY; Kang CI; Kim J; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
    Antimicrob Agents Chemother; 2014; 58(1):581-3. PubMed ID: 24126583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.